Alkermes plc

NASDAQ:ALKS

Biotechnology

Healthcare
$46.85 +1.77%

+$0.79 today

Market cap
$7.87B
Beta
0.33
P/E (TTM)
49.1
EPS (TTM)
$0.92
52W Low $25.17High $45.76

Volume 1.39M

Average 2.33M

ALKS Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Alkermes plcNASDAQ: ALKS

Total Equity · Q3 FY2026 · quarter ended Sep 2026

Total equity rises 7.6% from a year ago

Total equity stood at $1.86B at the end of Q3 FY2026, up 7.6% from a year earlier and up 3.1% from the prior quarter. Over 3 fiscal years it compounded at +20.3% a year.

Context

  • Total equity amounted to 42.0% of total assets at the end of Q3 FY2026, down 32.4 pp from a year earlier.
  • Total equity increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether total equity keeps rising in the next quarterly balance sheet after a +7.6% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.86B+3.1% QoQ
Last fiscal yearDec 2025
$1.82B+24.2% YoY
Year agoSep 2025
$1.73B+7.6% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.6%——
1 year+24.2%——
3-year CAGR+20.3%——
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
1.82B USD
Year-over-year change
+24.2%
4-year CAGR
+13.1%

Total Equity vs competitors

How ALKS compares with its peers on the latest reported figures

  • ALKS's Sep 2026 total equity of $1.86B is the 3rd highest of the 7 companies compared; the peer median is $1.21B.
  • Its year-over-year change of +7.6% is the 4th highest of 7, against a peer median of +9.9%.
  • Total equity amounts to 42.0% of total assets for ALKS, versus a peer median of 66.8%.
ALKS Competitors Peer median
Total Equity for ALKS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JAZZJazz Pharmaceuticals plcSep 2026$4.19B +5.9%+11.9%34.9%
NBIXNeurocrine Biosciences, Inc.Sep 2026$3.88B +29.1%+24.0%68.9%
ALKSAlkermes plcSep 2026$1.86B +7.6%+20.3%42.0%
ACADACADIA Pharmaceuticals Inc.Sep 2026$1.39B +51.3%+45.3%77.3%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$1.03B -3.1%+6.2%72.2%
VNDAVanda Pharmaceuticals Inc.Mar 2026$280.77M -45.1%-14.7%64.8%
AXSMAxsome Therapeutics, Inc.Jun 2026$83.3M +14.0%-6.9%10.9%
Peer median (excluding ALKS) $1.21B+9.9%+9.0%66.8%

Competitors are the stored peer set for ALKS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents337.54M292.47M457.47M291.15M1.12B
Short-term Investments198.77M315.99M316.02M460.52M199.65M
Net Receivables326.56M296.9M333.18M389.52M334.03M
Inventory150.34M181.42M186.41M182.89M196.63M
Other Current Assets043.53M192.43M91.28M79.09M
Total Current Assets1.06B1.13B1.49B1.42B1.93B
Property, Plant & Equipment (Net)456.68M320.46M318.4M311.81M298.93M
Goodwill92.87M83.03M83.03M83.03M0
Intangible Assets74.04M37.68M1.99M890K83.84M
Long-term Investments229.43M131.61M39.89M73.15M145K
Tax Assets81.83M114.57M195.89M154.84M169.08M
Other Non-current Assets27.46M146.33M11.52M16.5M49.1M
Total Non-current Assets962.32M833.67M650.72M640.21M601.09M
Total Assets2.02B1.96B2.14B2.06B2.53B
Account Payables55.72M32.84M65.65M45.63M107.95M
Short-term Debt3M3M3M06.75M
Tax Payables00000
Deferred Revenue6.34M6.82M2.73M1.25M0
Other Current Liabilities77.26M84.93M359.99M70.96M346.29M
Total Current Liabilities471.29M497.74M520.22M465.2M543.44M
Long-term Debt292.8M290.27M287.73M00
Deferred Tax Liabilities00(4.78M)043.26M
Deferred Revenue (Non-current)11.49M04.78M1.25M0
Other Non-current Liabilities32.16M55.93M49.88M54.77M61.01M
Total Non-current Liabilities440.61M422.48M413.32M125.39M167.52M
Total Liabilities911.9M920.23M933.54M590.59M710.96M
Common Stock1.66M1.69M1.73M1.77M1.81M
Retained Earnings(1.54B)(1.7B)(1.34B)(976.46M)(734.79M)
Accumulated OCI(3.72M)(10.89M)(3.11M)(1.97M)(2.1M)
Other Stockholders Equity00000
Minority Interest00000
Total Equity1.11B1.04B1.2B1.46B1.82B
Total Debt416.21M379.44M372.19M75.54M70M
Net Debt78.66M86.96M(85.28M)(215.61M)(1.05B)

Alkermes plc

NASDAQ:ALKS

Intrinsic Alpha fair value

Locked

Current Price

$46.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.